Compare LPTH & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | ARDX |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 996.8M |
| IPO Year | 2011 | 2014 |
| Metric | LPTH | ARDX |
|---|---|---|
| Price | $13.12 | $3.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $13.33 | ★ $15.14 |
| AVG Volume (30 Days) | 2.6M | ★ 4.8M |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,202,630.00 | $2,607,000.00 |
| Revenue This Year | $83.04 | $37.75 |
| Revenue Next Year | $24.83 | $34.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $4.71 | $3.73 |
| 52 Week High | $18.94 | $8.40 |
| Indicator | LPTH | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 27.01 |
| Support Level | $9.85 | N/A |
| Resistance Level | $16.06 | $6.47 |
| Average True Range (ATR) | 1.03 | 0.17 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 52.60 | 12.84 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.